



APRIL 2024

Shift Pharmaceuticals Engages OGAdvisors for Business Development and Transactional Support

Shift Pharmaceuticals is pleased to announce our engagement with OGAdvisors to provide business development and transactional support for SHC1A-012, our disease modifying Antisense Oligonucleotide (ASO). SHC1A-012 is being developed as a treatment for Charcot-Marie-Tooth Syndrome Type 1A (CMT1A), a rare progressive muscular neurodegenerative disease. Shifts' approach exploits exon-skipping sequences to knock down pre-RNA for the PMP22 protein, the excess of which is the cause of the disease. Early mouse studies show improvement in treated mice versus untreated mice across several metrics, including dowel traverse time, a measure of balance and speed.

“This partnership will allow Shift to accelerate the development of our CMT program and move our lead compound (SHC1A-012) to the clinic” noted Shift’s CEO, Steve O’Connor. “Onne Ganel and his team have extensive experience in this exact space, assisting with the early partnering efforts at DTx Pharma, which was recently acquired by Novartis”.

Onne Ganel, OGAdvisors’ founder, addressed the compound’s profile by stating “we are excited to be working with Shift on this opportunity. The data accumulated so far suggests the potential for lower dosing, more effective administration, and potentially overcoming of resistance mechanisms that may challenge other approaches, making it attractive for multiple potential partners”

OGAdvisors specializes in partnerships and transactions across the healthcare technology spectrum, serving pharmaceuticals, diagnostics, medical devices, and healthcare services clients.

ABOUT SHIFT PHARMACEUTICALS

Columbia, MO: Shift Pharmaceuticals (a privately held company) is developing Antisense Oligonucleotides as drug candidates for a variety of genetic disorders. Our first candidate (E1^{v1.11}) targets patients born with Spinal Muscular Atrophy (SMA). SMA occurs in 1:11,000 live births with devastating effects, often proving fatal for most patients under the age of 2. SMA is the leading genetic cause of infantile death worldwide and is marked by severe neurodegeneration and skeletal muscle wasting. Shift was co-founded by serial entrepreneur Dr. Steve O’Connor and world leading SMA research expert Dr. Chris Lorson. The company has licensed the core intellectual property from The University of Missouri, where the initial discovery and development was performed by Dr. Lorson. For more information, visit: www.shiftpharmaceuticals.com.



ABOUT OGADVISORS

OGAdvisors is a lifesciences technology advisory firm that was established in 2017. The firm specializes in partnerships and transactions including licensing, sponsored research and co-development effort, investments and acquisitions. In addition, OGAdvisors provides various advisory services such as transaction support, partnership project management, early-stage fundraising, and business and go-to-market strategies. www.ogadvisors.us.

CONTACT:

Shift Pharmaceuticals

Dr. Steve O'Connor, CEO

(626) 893-2514

steve.oconnor@shiftpharmaceuticals.com